We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 18, 2022

Anti–GM-CSF Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia

American Journal of Respiratory and Critical Care Medicine


Additional Info

American Journal of Respiratory and Critical Care Medicine
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
Am J Respir Crit Care Med 2022 Jun 01;205(11)1290-1299, GJ Criner, FM Lang, RL Gottlieb, KS Mathews, TS Wang, TW Rice, D Madduri, S Bellam, R Jeanfreau, AH Case, MK Glassberg, GM Lyon, K Ahmad, R Mendelson, JM DiMaio, MP Tran, CW Spak, JA Abbasi, SG Davis, S Ghamande, S Shen, L Sherman, S Lowry

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading